Sarah Gheuens Sells 4,091 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) insider Sarah Gheuens sold 4,091 shares of the firm's stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $34.17, for a total value of $139,789.47. Following the transaction, the insider owned 61,271 shares of the company's stock, valued at approximately $2,093,630.07. The trade was a 6.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Sarah Gheuens also recently made the following trade(s):

• On Tuesday, June 24th, Sarah Gheuens sold 2,909 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $33.54, for a total value of $97,567.86.

Agios Pharmaceuticals Price Performance

Shares of Agios Pharmaceuticals stock traded up $0.71 on Friday, reaching $36.06. The company had a trading volume of 258,713 shares, compared to its average volume of 652,247. The firm has a market cap of $2.09 billion, a price-to-earnings ratio of 3.21 and a beta of 0.73. The firm's 50-day moving average price is $31.92 and its two-hundred day moving average price is $31.98. Agios Pharmaceuticals, Inc. has a 1 year low of $23.42 and a 1 year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) EPS for the quarter, topping the consensus estimate of ($1.80) by $0.25. Agios Pharmaceuticals had a net margin of 1,798.26% and a negative return on equity of 2.75%. The company had revenue of $8.73 million during the quarter, compared to analyst estimates of $9.86 million. As a group, analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Scotiabank cut their target price on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a report on Friday, May 2nd. Wall Street Zen lowered shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday, May 19th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $58.60.

Hedge Funds Weigh In On Agios Pharmaceuticals

Large investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in Agios Pharmaceuticals by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company's stock worth $185,045,000 after purchasing an additional 85,339 shares during the last quarter. Erste Asset Management GmbH grew its position in Agios Pharmaceuticals by 10.9% in the 1st quarter. Erste Asset Management GmbH now owns 2,229,900 shares of the biopharmaceutical company's stock valued at $65,439,000 after acquiring an additional 220,000 shares during the last quarter. Jefferies Financial Group Inc. purchased a new stake in Agios Pharmaceuticals in the fourth quarter worth $49,290,000. Frazier Life Sciences Management L.P. lifted its position in shares of Agios Pharmaceuticals by 2.5% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 1,069,754 shares of the biopharmaceutical company's stock worth $35,152,000 after purchasing an additional 25,600 shares during the last quarter. Finally, Deutsche Bank AG lifted its position in shares of Agios Pharmaceuticals by 39.7% during the fourth quarter. Deutsche Bank AG now owns 935,252 shares of the biopharmaceutical company's stock worth $30,732,000 after purchasing an additional 265,637 shares during the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.